viewShield Therapeutics PLC

Shield Therapeutics: Analyst discusses further positive data from non-inferiority Feraccru study

Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study.

It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose (IV FCM), which is the standard second-line treatment for iron deficiency anaemia (IDA).

Ulker says the data from the multi-national phase 3b randomised trial in inflammatory bowel disease (IBD) patients with IDA, supports the headline data reported back in March and provides additional material to support commercialisation and reimbursement efforts.

Click here to read Emma Ulker's latest note Shield Therapeutics PLC: Hitting its clinical targets

Quick facts: Shield Therapeutics PLC

Price: 165 GBX

Market: LSE
Market Cap: £193.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...



Full interview: Shield Therapeutics ties up US$63mln deal for Feraccru in China

Shield Therapeutics (LON:STX) has signed an exclusive agreement worth up to US$63mln for its iron deficiency treatment Feraccru to be sold in China. Chief Executive Carl Sterritt came to talk to us at Proactive London and he couldn't hide his enthusiasm at the deal making it over the line,...

1 week, 2 days ago

2 min read